SLC5A2 and atrial fibrillation: Comparative Analysis with Other Glucose-Lowering Therapies: Our study's finding of no significant causal association between DPP4 gene expression/inhibition and AF contrasts with the documented benefits of SGLT2 inhibitors and GLP-1 receptor agonists on AF outcomes [53].